Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488978 | 0.86 | PPARD (0.50) | PPARDHDAC1TSHRPOLBENPP2 | |
| SCHEMBL6776837 | 0.83 | TSHR (0.41) | PPARDHDAC1TSHRPOLBNPSR1 | |
| SCHEMBL10967058 | 0.83 | LAP3 (0.34) | TSHRPOLBENPP2LMNA | |
| SCHEMBL915800 | 0.81 | TSHR (0.52) | PPARDTSHRPOLBCETPNPSR1 | |
| SCHEMBL915441 | 0.79 | PPARD (0.44) | PPARDHDAC1POLBENPP2CETP | |
| Phosphoric Acid SCHEMBL8605342 | 0.79 | CETP (0.50) | PPARDTSHRPOLBCETPNPSR1 | |
| SCHEMBL914541 | 0.79 | PPARD (0.44) | PPARDHDAC1TSHRPOLBENPP2 | |
| SCHEMBL6769157 | 0.79 | TSHR (0.38) | PPARDHDAC1TSHRPOLBNPSR1 | |
| SCHEMBL6045256 | 0.78 | PPARD (0.50) | PPARDHDAC1TSHRPOLBCETP | |
| SCHEMBL915280 | 0.78 | FDPS (0.46) | PPARDHDAC1TSHRPOLBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720344-B2 | BINDING TO NUCLEAR RECEPTOR PROTEINS; STIMULATING BMP-2 PROMOTER ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-13 | — | — | US | disclosed |
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | KERWIN SEAN M (US) | 2003-06-26 | — | — | US | disclosed |
| EP-0912549-A4 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | UNIV TEXAS (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0912549-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048694-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-12-24 | — | — | WO | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | MKI67, HGF, AREG | PPARD 225/4885HDAC1 1027/4885TSHR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.